首页> 外文期刊>Molecular cancer therapeutics >Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
【24h】

Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.

机译:基质金属蛋白酶激活的炭疽致死性毒素的细胞毒性取决于人类黑素瘤细胞中的明胶酶表达和B-RAF状态。

获取原文
获取原文并翻译 | 示例
           

摘要

Anthrax lethal toxin (LeTx) shows potent mitogen-activated protein kinase pathway inhibition and apoptosis in melanoma cells that harbor the activating V600E B-RAF mutation. LeTx is composed of two proteins, protective antigen and lethal factor. Uptake of the toxin into cells is dependent on proteolytic activation of protective antigen by the ubiquitously expressed furin or furin-like proteases. To circumvent nonspecific LeTx activation, a substrate preferably cleaved by gelatinases was substituted for the furin LeTx activation site. Here, we have shown that the toxicity of this matrix metalloproteinase (MMP)-activated LeTx is dependent on host cell surface MMP-2 and MMP-9 activity as well as the presence of the activating V600E B-RAF mutation, making this toxin dual specific. This additional layer of tumor cell specificity would potentially decrease systemic toxicity from the reduction of nonspecific toxin activation while retaining antitumor efficacy in patients with V600E B-RAF melanomas. Moreover, our results indicate that cell surface-associated gelatinase expression can be used to predict sensitivity among V600E B-RAF melanomas. This finding will aid in the better selection of patients that will potentially respond to MMP-activated LeTx therapy. [Mol Cancer Ther 2008;7(5):1218-26].
机译:炭疽致死性毒素(LeTx)在具有激活性V600E B-RAF突变的黑色素瘤细胞中显示出强大的促丝裂原激活蛋白激酶途径抑制作用和凋亡。 LeTx由两种蛋白质组成,保护性抗原和致死因子。毒素进入细胞取决于遍在表达的弗林蛋白酶或弗林蛋白酶样蛋白酶对保护性抗原的蛋白水解激活。为了规避非特异性LeTx激活,将优选被明胶酶切割的底物替换为弗林蛋白酶LeTx激活位点。在这里,我们已经表明,这种基质金属蛋白酶(MMP)激活的LeTx的毒性取决于宿主细胞表面MMP-2和MMP-9活性以及激活的V600E B-RAF突变的存在,从而使这种毒素双重具体。肿瘤细胞特异性的这一额外层可能会通过降低非特异性毒素激活而降低全身毒性,同时保留V600E B-RAF黑色素瘤患者的抗肿瘤功效。此外,我们的结果表明,细胞表面相关的明胶酶表达可用于预测V600E B-RAF黑色素瘤之间的敏感性。这一发现将有助于更好地选择可能对MMP激活的LeTx治疗有反应的患者。 [Mol Cancer Ther 2008; 7(5):1218-26]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号